Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)

Next Previous
Trial Profile

A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AST 201 (Primary) ; Carboplatin; Paclitaxel; Sargramostim
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms Cornerstone-004; Cornerstone4
  • Sponsors Aston Science

Most Recent Events

  • 12 Sep 2023 According to Aston Sci. media release, company has received Phase 2 Clinical Investigational New Drug approval from the U.S. Food and Drug Administration for its innovative cancer vaccine, AST-201 for ovarian cancer.
  • 19 Jul 2023 Planned End Date changed from 15 Aug 2027 to 15 Nov 2027.
  • 18 Jul 2023 Planned primary completion date changed from 15 Oct 2025 to 15 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top